IgM Myeloma: Report of Two Cases of a Rare Entity with Unusual Immunophenotype.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4901-4901
Author(s):  
Anas Al-Janadi ◽  
Karng S. Log ◽  
Prashanth Peddi ◽  
Brian Olsen

Abstract Abstract 4901 Introduction Plasma cell myeloma is characterized by clonal proliferation of plasma cells and serum and/or urine paraprotein, most commonly IgG, IgA or light chain only. IgM, IgD, IgE and non-secretory variants are infrequent. IgM myeloma comprises less than 0.5% of myelomas. These should not be confused with B-cell non-Hodgkin lymphoma showing plasmacytoid differentiation and an IgM paraprotein, particularly lymphoplasmacytic lymphoma. Two cases are reported herein. Case 1 A 57 year old female with known MGUS, type II diabetes, rheumatoid arthritis, underwent total thyroidectomy for papillary thyroid carcinoma. Two months later she required excision of a cervical lymph node, identified by radioactive iodine scanning, revealing metastatic papillary thyroid carcinoma. However, during pre-operative evaluation, cytopenias were noted (hemoglobin 7.8 g/dL, platelets 86 × 109L), and renal insufficiency (creatinine 2.1 mg/dL). Subsequent laboratory findings included a serum IgM kappa paraprotein of 6158 mg/dL, normal IgA, decreased IgG of 423 mg/dL, elevated beta-2 microglobulin (7.7 mg/L), elevated serum viscosity (3 cp), mildly decreased serum calcium (8.2 mg/dL). A skeletal survey was negative. Pathologic findings: Peripheral blood showed pancytopenia, marked RBC rouleaux, and occasional atypical plasmacytoid cells (5%). Bone marrow biopsy sections revealed marked hypercellularity with a predominance of plasmacytoid cells. By immunohistochemistry (IHC), these were CD138+, CD117+. MUM1+, weak cytoplasmic kappa+, weak CD79a+, CD45-, CD19-, CD20-, PAX 5-, CD5-, CD10-, CD23-, CD56-, cyclin D1-. Flow cytometry (FC) of peripheral blood also revealed abnormal cells, of comparable phenotype (CD45-, CD19-, CD20-, CD38+, CD138+, CD56-), though CD117 and cytoplasmic light chain expression were not evident. Clinical course: Management included plasma exchange for serum hyperviscosity, pulse steroids and thalidomide. Despite these interventions, her condition worsened, including a progressive decline in renal function, requiring hemodialysis. Eventually she declined further treatment, and expired two months after diagnosis. Case 2 An 83 year old male patient presented with fatigue, dyspnea, diffuse pain, paresthesias involving hands and feet of two weeks duration. Past history was remarkable for COPD, lower extremity DVT, and hyperlipidemia. Physical examination revealed no lymphadenopathy or organomegaly. Laboratory studies revealed pancytopenia, IgM kappa paraprotein of 4664 mg/dL, normal serum IgG, diminished IgA, elevated serum creatinin (1.7 mg/dL), normal serum calcium, elevated beta-2 microglobulin (4.9 mg/L) and elevated serum viscosity (3.4 cp). A skeletal survey was negative. Pathologic findings: Peripheral blood revealed pancytopenia with marked RBC rouleaux. Marrow aspirate smears showed abundant abnormal plasma cells, many showing numerous, azurophilic, crystalline cytoplasmic inclusions, Auer rod-like. Bone marrow biopsy was hypercellular and heavily infiltrated by abnormal plasma cells. By IHC, these were CD138+, MUM1+, cyclin D1+, CD56+, cytoplasmic kappa+, CD20+ (sub-set), weak CD117+. FC of marrow aspirate yielded comparable results (CD56 co-expression, bright CD38+ and CD138+, CD19-, CD20-, CD45-). Conventional cytogenetics revealed a normal male karyotype. Interphase FISH revealed t(11; 14), trisomies 11, 13, 14 and 17, with 13q14 and 17p13 deletions. Clinical course: The patient rapidly deteriorated, and expired shortly after hospital admission. Conclusion We describe two cases of IgM myeloma. The diagnosis in each case was supported by morphology and immunophenotype and, in one case, by interphase FISH. These add to our limited knowledge regarding the biology of this disorder. Recently, it has been suggested that such cases are of relatively uniform immunophenotype, in particular lacking either CD56 or CD117 expression (Feyler S et al, BJH 140, 547-551, 10/2007). Our cases show that the spectrum of immunophenotypic findings in IgM myeloma is broader than has been suggested. In addition, one of the two cases showed Auer-rod like crystalline cytoplasmic inclusions in malignant plasma cells, also a rare finding in this setting. Disclosures No relevant conflicts of interest to declare.

1997 ◽  
Vol 77 (05) ◽  
pp. 0868-0872 ◽  
Author(s):  
Li Sheng ◽  
Ann Soumillion ◽  
Kathelijne Peerlinck ◽  
Chris Verslype ◽  
Lan Lin ◽  
...  

SummaryThe hepatitis G virus (HGV) has recently been identified as a new member of the Flaviviridae family. Infection by this virus is thought to be associated with blood borne hepatitis. In this study, the presence of HCV- and HGV-RNAs in serum or plasma (175 patients) and in peripheral blood mononuclear cells (PBMC) (133 patients) was investigated in patients with clotting disorders using a sensitive reverse transcriptase polymerase chain reaction (RT-PCR). HGV-RNA was detected in serum of 26 patients (14.8%). In apparently healthy blood donors, serum HGV-RNA was detected in 4 of 358 individuals investigated (1.12%). Ninety two percent of the 26 serum HGV-RNA positive patients had coinfection with the hepatitis C virus (HGV), especially with HCV genotype lb, the most common genotype in Belgium. Of these coinfected patients, 15 (62.5%) showed elevated serum ALT levels. Two patients who were solely infected with HGV had normal serum ALT. HGV-RNA in PBMC was found in 18 patients, of whom 3 were negative for serum HGV-RNA. As in case of HCV, HGV-RNA in PBMC is preferentially sensitive to interferon treatment. Nevertheless, rapid reappearance of HGV-RNA in PBMC was observed after cessation of treatment. In one patient, persistent serum ALT elevation seems to be associated with continued HGV viremia, despite the disappearance of serum HCV-RNA.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5210-5210
Author(s):  
Hawk Kim ◽  
Shin Kim ◽  
M. Wookun Kim ◽  
Jung-Shin Lee ◽  
Cheolwon Suh

Abstract Absolute lymphocyte count (ALC) ≥1000 cells/mm3 on day +23 was an independent predictor of prolonged survival in patients with T/NK-cell lymphoma after autologous peripheral blood stem cell transplantation (APBSCT). To understand the prognostic value of lymphocyte recovery, we performed a retrospective study analyzing the result of 59 patients with multiple myeloma (MM) patients who underwent APBSCT. All patients were in complete or partial response after APBSCT. A median age at APBSCT was 51. Peripheral blood stem cells were mobilized and collected after cytoxan and G-CSF. The conditioning regimen was melphalan 200. ALC recovery day was defined as a first day of 3 consecutive days when ALC has been recovered more than 1000/mm3. A median value was used for the analysis of each noncategorical variable. A median follow-up time after APBSCT was 33.8 months and median recovery days of ALC ≥1000 cells/mm3 was 23 days. Prognostic factors at the time of APBSCT for transplant OS and PFS included beta-2 microglobulin, serum albumin, recovery days of neutrophil ≥500/mm3, infused mononuclear cell dose, infused CD+34 cell dose and recovery days of ALC ≥1000 cells/mm3. Univariate analysis revealed that significant variables at APBSCT for overall survival (OS) were beta-2 microglobulin, day of neutrophil engraftment and recovery days of ALC. Positive predictors at APBSCT for progression-free survival (PFS) were beta-2 microglobulin, day of neutrophil engraftment, serum albumin, infused mononuclear cell count, infused CD +34 cell count and recovery days of ALC. ALC ≥1000 cells/μL on day +23 was an independent predictive prognostic factors for better PFS (P = 0.003; Relative risk (RR) = 3.710; 95% Confidence interval (CI), 1.576–8.736) and showed tendency for prolonged OS (P = 0.065; RR=2.411; 95% CI, 0.946–6.142) (Table 1).In conclusion, ALC ≥1000 cells/mm3 recovery on day +23 was a good predictor for better survival in MM after APBSCT. Table 1. Multivariate analysis for OS and PFS Variables OS PFS RR 95% CI P RR 95% CI P ANC, absolute neutrophil count; MNC, Mononuclear cell; ALC, absolute lymphocyte count β2 microglobulin ≤ 3 vs > 3 mg/l 3.497 1.32–9.25 0.012 2.215 0.962–5.101 0.062 Serum albumin ≤ 3.7 vs > 3.7 g/dl 0.337 0.139–0.816 0.016 ANC≥ 500/mm³ recovery days≤ 11 vs > 11 2.677 1.044–6.864 0.040 1.360 0.616–3.001 0.447 Infused MNC dose≤ 3.4 vs > 3.4 ×10^8/kg 1.351 0.552–3.310 0.510 Infused CD+34 dose≤ 6 vs > 6 ×10^6/kg 0.609 0.209–1.779 0.365 ALC≥ 1000/mm³ recovery days≤ 23 vs > 23 2.411 0.946–6.142 0.065 3.710 1.576–8.736 0.003


1993 ◽  
Vol 11 (6) ◽  
pp. 1108-1111 ◽  
Author(s):  
M A Dimopoulos ◽  
F Cabanillas ◽  
J J Lee ◽  
F Swan ◽  
L Fuller ◽  
...  

PURPOSE To evaluate the role of serum beta 2-microglobulin (beta 2M) in the prognosis of patients with Hodgkin's disease. PATIENTS AND METHODS One hundred sixty previously untreated patients with Hodgkin's disease had serum beta 2M levels determined before initiation of treatment. Serum beta 2M was tested for its correlation with known prognostic factors for patients with Hodgkin's disease. These variables, including beta 2M, were correlated with complete remission (CR) rate and time to treatment failure (TTF). Univariate and multivariate analyses were performed. RESULTS Serum beta 2M levels greater than 2.5 mg/L were found in 29% of patients. Such elevation was more common in patients with more advanced-stage disease. Elevated serum beta 2M was an independent and powerful factor in the prediction of lower response rate and shorter TTF. Its impact appeared to be more significant in patients with advanced disease. CONCLUSION Serum beta 2M appears to correlate with tumor stage in patients with Hodgkin's disease and elevated serum levels of this polypeptide predict a less favorable prognosis.


1981 ◽  
Vol 20 (2) ◽  
pp. 114-118
Author(s):  
Tadahiro HOTTA ◽  
Toshikazu YOSHIKAWA ◽  
Keiji FUKUMOTO ◽  
Kyohei YAMAGUCHI ◽  
Motoharu KONDO ◽  
...  

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 5003-5003
Author(s):  
Liang-Tsai Hsiao ◽  
Tzeon-Jye Chiou ◽  
Ying-Chung Hong ◽  
Chun-Yu Liu ◽  
Yuan-Bin Yu ◽  
...  

Abstract Abstract 5003 Background & aims. For patients with multiple myeloma (MM), comorbid type II diabetes mellitus (DM) has leaded additional consideration and complications. Preceding DM in MM patients may have lead to end-organ damage involving cardiovascular, renal and nervous systems, and the use of glucocorticoids - the mainstay of anti-myeloma agents - further impairs glycemic control. However, it is not well studied at present whether comorbid DM itself will influence clinical features and prognosis of MM patients. Methods. Patients who were newly diagnosed in Taipei Veterans General Hospital between 1996 and 2007 were enrolled. Data of clinical features, comorbidities, and laboratory tests at diagnosis, treatment modalities, and survival at last follow up were collected. MM patients with or without DM was compared in terms of clinical/laboratory tests and outcome. Results. There were 389 MM patients (M/F=288/101, 74% vs. 26%) with median age of 71 years, with the features summarized in the Table. The immunophenotypes consisted of IgG (194, 49.9%), IgA (113, 29%), and light chain diseases (LCD) (67, 17.2%). Clinical stages included Durie-Salmon (DS) stage I/II/III = 7.2%/20.1%/72.7% and International Staging System (ISS) stage I/II/III = 14.5%/29.3%/56.2%. Serum Cr > 2.0 mg/dL at diagnosis was noted in 34%. Sixty patients (15.4% of 389) had DM preceding the diagnosis of MM. There was no statistical difference of median age, gender distribution, DS stages, and renal impairment when comparing MM patients with or without comorbid DM.MM patients with comorbid DM were associated with a lower prevalence of IgA-type diseases (with vs. without DM= 17% vs. 32%, P=0.094), an elevated serum beta-2 microglobulin >5 mg/L (with vs. without DM = 75% vs. 52%, P=.006), and ISS-stage III disease (with vs. without DM = 75% vs. 53%, P=.005). In terms of anti-myeloma therapy, the proportion of MM patients with or without DM who once received thalidomide, bortezomib and high-dose chemotherapy plus stem cell transplantation (HDT and SCT), and bisphosphonates were similar. The median overall survival (OS) of all patients was 20.5 months. The OS was well correlated with ISS stages (I vs. II vs. III = 51.2 vs. 27.2 vs. 13.4 months, P<0.001) but was not with comorbid DM. Conclusions. Comorbid DM was present in up to 15% of MM patients, and was more frequently associated with elevated serum beta-2 microglobulin (>5 mg/L) and ISS-stage III diseases; however, comorbid DM did not significantly influence the OS. Therefore, comorbid DM itself should not be considered as a contraindication of aggressive anti-myeloma treatments at present. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1821-1821
Author(s):  
Seyoung Seo ◽  
Jung Yong Hong ◽  
Dok Hyun Yoon ◽  
Jaekyung Cheon ◽  
Chan-Sik Park ◽  
...  

Abstract Background Novel treatment strategies, such as non-anthracycline-based chemotherapy and upfront use of concurrent chemoradiotherapy or radiotherapy have markedly improved the survival outcome of extranodal natural killer/T cell lymphoma (ENKTL). Recently, a new prognostic model, Prognostic Index of Natural killer cell lymphoma (PINK) was proposed for predicting clinical outcomes of ENKTL patients treated with non-anthracycline-based strategies. Elevated serum beta-2 microglobulin (B2M) had been suggested as a potential prognostic predictor for patients with ENKTL, but there was no prognostic model including serum B2M level. We investigated the prognostic role of serum B2M level and suggested a new prognostic index by incorporating serum B2M level into PINK in patients with ENKTL. Methods We retrospectively identified 98 patients who received non-anthracycline-based treatment for newly diagnosed ENKTL in Asan Medical Center between January 2005 to December 2014. Serum beta-2 microglobulin level was measured using a radioimmunoassay kit (Immunotech, Inc., Prague, Czech Republic). The optimal cutoff point of serum beta-2 microglobulin level was estimated using ROC curve analysis. We developed a new prognostic model (PINK-B) with 4 elements of PINK (Age>60 years, Ann arabor Stage ¥²-¥³, distant lymph node involvement, and non-nasal type disease) plus serum B2MG level. We performed a validation analysis of a new prognostic model (PINK-B) in an independent cohort. Result Baseline characteristic were summarized in Table 1. Median B2M value was 2.35 mg/L (range, 1.0-22.0) and the optimal cutoff value of serum B2M level for predicting 3-year overall survival (OS) was ¡Ã2.8 mg/L. Baseline serum B2M elevation (¡Ã2.8 mg/L) was observed in 39 patients (39.8%). In univariate analysis, elevated B2M level (¡Ã2.8 mg/L) was significantly associated with poorer OS (HR=3.83 ;95% CI: 2.06-7.09; p<0.001). We performed multivariate analysis including 4 factors of PINK and elevated serum B2M level. In the multivariate analysis, elevated serum B2M level retained its significant poor prognostic impact for OS (HR=2.13 ;95% CI: 1.09-4.17; p=0.028). Three risk groups in PINK-B were composed as followings: low risk (0-1 points), intermediate risk (2-3 points), and high risk (4 or more points). PINK-B showed better discriminative power compared with PINK for predicting 3-year OS of low-, intermediate-, and high-risk group: 79.5%, 70.0%, and 18.6% for PINK, 78.3%, 40.9%, and 13.5% for PINK-B, respectively. (Figure 1.) The C-indices for PINK and PINK-B were 0.72 (95% CI: 0.62-0.82) and 0.74 (95% CI: 0.64-0.84). We applied PINK and PINK-B to an independent cohort of 90 newly diagnosed ENKTL patients. The performance of PINK and PINK-B for predicting probabilities was validated and 3-years OS of low-, intermediate-, and high-risk groups were 80.2%, 68.7%, and 9.4% for PINK and 80.3%, 31.3%, and 9.5% for PINK-B, respectively (Figure 2.) Conclusion We suggest a new version of prognostic index (PINK-B : PINK combined with elevated serum B2M) for ENKTL patients treated with non-anthracycline-based strategies. Table 1 Comparison of baseline characteristics between the training cohort and validation cohort Table 1. Comparison of baseline characteristics between the training cohort and validation cohort Figure 1 overall survival according to PINK, PINK-E, PINK-B in the training cohort Figure 1. overall survival according to PINK, PINK-E, PINK-B in the training cohort Figure 2 overall survival according to PINK, PINK-E, PINK-B in the validation cohort Figure 2. overall survival according to PINK, PINK-E, PINK-B in the validation cohort Disclosures Kim: Celltrion, Inc.: Consultancy, Honoraria.


Infection ◽  
1988 ◽  
Vol 16 (2) ◽  
pp. 109-110 ◽  
Author(s):  
Linda Morfeldt-Månson ◽  
Inger Julander ◽  
L. V. von Stedingk ◽  
J. Wasserman ◽  
B. Nilsson

Sign in / Sign up

Export Citation Format

Share Document